{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T19:23:03Z","timestamp":1790364183186,"version":"4.1.0"},"reference-count":50,"publisher":"BMJ","license":[{"start":{"date-parts":[[2021,1,29]],"date-time":"2021-01-29T00:00:00Z","timestamp":1611878400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Objective<\/jats:title>\n            <jats:p>To evaluate the association between human\n                                                  papillomavirus (HPV) vaccination and serious\n                                                  adverse events in adolescent girls in South\n                                                  Korea.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Design<\/jats:title>\n            <jats:p>Cohort study.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Setting<\/jats:title>\n            <jats:p>A large linked database created by linking the\n                                                  Korea Immunization Registry Information System and\n                                                  the National Health Information Database, between\n                                                  January 2017 and December 2019.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Participants<\/jats:title>\n            <jats:p>441\u2009399 girls aged 11-14 years who had been\n                                                  vaccinated in 2017: 382\u2009020 had been vaccinated\n                                                  against HPV and 59\u2009379 had not been vaccinated\n                                                  against HPV.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Main outcome measures<\/jats:title>\n            <jats:p>Outcomes were 33 serious adverse events,\n                                                  including endocrine, gastrointestinal,\n                                                  cardiovascular, musculoskeletal, haematological,\n                                                  dermatological, and neurological diseases. A\n                                                  cohort design was used for the primary analysis\n                                                  and a self-controlled risk interval design for the\n                                                  secondary analysis; both analyses used a risk\n                                                  period of one year after HPV vaccination for each\n                                                  outcome. Incidence rate and adjusted rate ratios\n                                                  were estimated using Poisson regression in the\n                                                  primary analysis, comparing the HPV vaccinated\n                                                  group with the HPV unvaccinated group, and\n                                                  adjusted relative risks were estimated using\n                                                  conditional logistic regression in the secondary\n                                                  analysis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>\n              Among the 33 predefined serious adverse events,\n                                                  no associations were found with HPV vaccination in\n                                                  the cohort analysis, including Hashimoto\u2019s\n                                                  thyroiditis (incidence rate per 100\u2009000 person\n                                                  years: 52.7\n              <jats:italic>v<\/jats:italic>\n              36.3 for the\n                                                  vaccinated and unvaccinated groups; adjusted rate\n                                                  ratio 1.24, 95% confidence interval 0.78 to 1.94)\n                                                  and rheumatoid arthritis (incidence rate per\n                                                  100\u2009000 person years: 168.1\n              <jats:italic>v<\/jats:italic>\n              145.4 for the vaccinated and unvaccinated groups;\n                                                  0.99, 0.79 to 1.25), with the exception of an\n                                                  increased risk observed for migraine (incidence\n                                                  rate per 100\u2009000 person years: 1235.0\n              <jats:italic>v<\/jats:italic>\n              920.9 for the vaccinated and\n                                                  unvaccinated groups; 1.11, 1.02 to 1.22).\n                                                  Secondary analysis using self-controlled risk\n                                                  intervals confirmed no associations between HPV\n                                                  vaccination and serious adverse events, including\n                                                  migraine (adjusted relative risk 0.67, 95%\n                                                  confidence interval 0.58 to 0.78). Results were\n                                                  robust to varying follow-up periods and for\n                                                  vaccine subtypes.\n            <\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>In this nationwide cohort study, with more than\n                                                  500\u2009000 doses of HPV vaccines, no evidence was\n                                                  found to support an association between HPV\n                                                  vaccination and serious adverse events using both\n                                                  cohort analysis and self-controlled risk interval\n                                                  analysis. Inconsistent findings for migraine\n                                                  should be interpreted with caution considering its\n                                                  pathophysiology and the population of\n                                                  interest.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1136\/bmj.m4931","type":"journal-article","created":{"date-parts":[[2021,1,29]],"date-time":"2021-01-29T12:20:13Z","timestamp":1611922813000},"page":"m4931","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":29,"title":["Association between human papillomavirus vaccination and serious adverse events in South Korean adolescent girls: nationwide cohort study"],"prefix":"10.1136","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9369-0789","authenticated-orcid":false,"given":"Dongwon","family":"Yoon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2230-131X","authenticated-orcid":false,"given":"Ji-Ho","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6556-9984","authenticated-orcid":false,"given":"Hyesung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1010-7525","authenticated-orcid":false,"given":"Ju-Young","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,1,29]]},"reference":[{"key":"2021012908150838000_372.jan28_3.m4931.1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.30716"},{"key":"2021012908150838000_372.jan28_3.m4931.2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.29210"},{"key":"2021012908150838000_372.jan28_3.m4931.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2012.05.039"},{"key":"2021012908150838000_372.jan28_3.m4931.4","unstructured":"Global HPV vaccine introduction overview: projected and current national introductions, demonstration\/pilot projects, gender-neutral vaccination programs, and global HPV vaccine introduction maps (2006-2022). 2019 https:\/\/path.azureedge.net\/media\/documents\/GlobalHPVVaccineIntroOverview_Nov2019.pdf (accessed 26 September 2020)."},{"key":"2021012908150838000_372.jan28_3.m4931.5","unstructured":"Schedules and strategies for human papillomavirus (HPV) immunization: World Health Organization; 2016 [updated 27 September 2016. https:\/\/www.who.int\/immunization\/sage\/meetings\/2016\/october\/1_HPV_vaccine_background_document_27Sept2016.pdf?ua=1"},{"key":"2021012908150838000_372.jan28_3.m4931.6","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2018.33.e331"},{"key":"2021012908150838000_372.jan28_3.m4931.7","unstructured":"National Immunization Program for children 2019 [updated 16 July 2019]. http:\/\/www.cdc.go.kr\/contents.es?mid=a30301140000 (accessed 1 March 2020)."},{"key":"2021012908150838000_372.jan28_3.m4931.8","unstructured":"Recommendation of HPV immunization for adolescent girls born between 2006 to 2007 Korea Centers for Disease Control and Prevention, 2019. https:\/\/nip.cdc.go.kr\/irgd\/support.do?service=getNewsView&strNum=252&PROSEQNUM=429&SEARCHTYPE=&SEARCHWARD= (accessed 20 March 2020)."},{"key":"2021012908150838000_372.jan28_3.m4931.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2017.05.071"},{"key":"2021012908150838000_372.jan28_3.m4931.10","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-019-0983-y"},{"key":"2021012908150838000_372.jan28_3.m4931.11","unstructured":"Survey of attitudes toward human papillomavirus vaccine vaccination 2017 https:\/\/www.cdc.go.kr\/board\/board.es?mid=a205010000000&bid=0015&act=view&list_no=75836&tag=&nPage=112 (accessed 4 June 2020)."},{"key":"2021012908150838000_372.jan28_3.m4931.12","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.16946"},{"key":"2021012908150838000_372.jan28_3.m4931.13","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f5906"},{"key":"2021012908150838000_372.jan28_3.m4931.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2017.06.030"},{"key":"2021012908150838000_372.jan28_3.m4931.15","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m2930"},{"key":"2021012908150838000_372.jan28_3.m4931.16","doi-asserted-by":"publisher","DOI":"10.1111\/joim.12694"},{"key":"2021012908150838000_372.jan28_3.m4931.17","doi-asserted-by":"publisher","DOI":"10.1111\/joim.12155"},{"key":"2021012908150838000_372.jan28_3.m4931.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.09.087"},{"key":"2021012908150838000_372.jan28_3.m4931.19","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2016.1199308"},{"key":"2021012908150838000_372.jan28_3.m4931.20","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyw253"},{"key":"2021012908150838000_372.jan28_3.m4931.21","unstructured":"Park EJS Jeon S Lee S Lee J Choi D . Report of the evaluation for validity of discharged diagnoses in Korean Health Insurance database. Health Insurance Review and Assessment Service, 2017."},{"key":"2021012908150838000_372.jan28_3.m4931.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2012.04.103"},{"key":"2021012908150838000_372.jan28_3.m4931.23","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2019.34.e105"},{"key":"2021012908150838000_372.jan28_3.m4931.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.08.117"},{"key":"2021012908150838000_372.jan28_3.m4931.25","doi-asserted-by":"publisher","DOI":"10.1586\/14760584.2016.1123097"},{"key":"2021012908150838000_372.jan28_3.m4931.26","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4175"},{"key":"2021012908150838000_372.jan28_3.m4931.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.02.019"},{"key":"2021012908150838000_372.jan28_3.m4931.28","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3593"},{"key":"2021012908150838000_372.jan28_3.m4931.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.02.034"},{"key":"2021012908150838000_372.jan28_3.m4931.30","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-019-00881-9"},{"key":"2021012908150838000_372.jan28_3.m4931.31","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-017-0574-6"},{"key":"2021012908150838000_372.jan28_3.m4931.32","doi-asserted-by":"publisher","DOI":"10.1007\/s12026-014-8575-3"},{"key":"2021012908150838000_372.jan28_3.m4931.33","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwu322"},{"key":"2021012908150838000_372.jan28_3.m4931.34","doi-asserted-by":"publisher","DOI":"10.4161\/hv.21268"},{"key":"2021012908150838000_372.jan28_3.m4931.35","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-015-0503-y"},{"key":"2021012908150838000_372.jan28_3.m4931.36","doi-asserted-by":"publisher","DOI":"10.1186\/s12978-016-0240-y"},{"key":"2021012908150838000_372.jan28_3.m4931.37","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.2011.02467.x"},{"key":"2021012908150838000_372.jan28_3.m4931.38","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000002569"},{"key":"2021012908150838000_372.jan28_3.m4931.39","first-page":"A5064","article-title":"Suspected side effects to the\n                                                  quadrivalent human papilloma\n                                                  vaccine","volume":"62","author":"Brinth","year":"2015","journal-title":"Dan Med\n                                                  J"},{"key":"2021012908150838000_372.jan28_3.m4931.40","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-014-2444-x"},{"key":"2021012908150838000_372.jan28_3.m4931.41","doi-asserted-by":"publisher","DOI":"10.4178\/epih\/e2014008"},{"key":"2021012908150838000_372.jan28_3.m4931.42","doi-asserted-by":"publisher","DOI":"10.1080\/10543406.2015.1052819"},{"key":"2021012908150838000_372.jan28_3.m4931.43","doi-asserted-by":"publisher","DOI":"10.1542\/peds.114.1.187"},{"key":"2021012908150838000_372.jan28_3.m4931.44","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-019-1032-6"},{"key":"2021012908150838000_372.jan28_3.m4931.45","doi-asserted-by":"publisher","DOI":"10.1111\/j.1475-6773.2005.00444.x"},{"key":"2021012908150838000_372.jan28_3.m4931.46","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013479"},{"key":"2021012908150838000_372.jan28_3.m4931.47","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(14)70237-2"},{"key":"2021012908150838000_372.jan28_3.m4931.48","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6604766"},{"key":"2021012908150838000_372.jan28_3.m4931.49","doi-asserted-by":"publisher","DOI":"10.1111\/jog.12822"},{"key":"2021012908150838000_372.jan28_3.m4931.50","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-2667(20)30010-4"}],"container-title":["BMJ"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/data.bmj.org\/tdm\/10.1136\/bmj.m4931","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmj.m4931","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,29]],"date-time":"2021-01-29T16:15:33Z","timestamp":1611936933000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.bmj.com\/lookup\/doi\/10.1136\/bmj.m4931"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,29]]},"references-count":50,"alternative-id":["10.1136\/bmj.m4931"],"URL":"https:\/\/doi.org\/10.1136\/bmj.m4931","relation":{},"ISSN":["1756-1833"],"issn-type":[{"value":"1756-1833","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,29]]}}}